Dr. Paul Doghramji joins Dr. Wenxin Xu, a physician at the Dana-Farber Cancer Institute and an Instructor in Medicine at Harvard Medical School, to take a look at some of the key factors guiding treatment decisions and disease management for patients with advanced renal cell carcinoma.

Dr. Rana Mckay, a Medical Oncologist and Assistant Professor of Medicine at the University of California San Diego, explores the role of surveillance and frontline local therapy for patients with advanced renal cell carcinoma

Head and neck squamous cell carcinomas (HNSCC) represent a significant healthcare burden due to associated morbidity and mortality. Most patients survive less than a year after diagnosis and report a poor quality of life. Tune in to this chapterized content as two leading experts, Drs. Ezra Cohen and Barbara Burtness, discuss recent clinical trial data and strategies to improve sequencing and treatment selection. Find out how checkpoint inhibitors are shifting the treatment landscape of HNSCC and what this means for your patients.

ReachMD hosts Drs. Matt Birnholz and Jacob Sands come together to discuss the rationales, limitations, and pathways forward in the treatment of relapsing small cell lung cancer as well as platinum rechallenge therapy.

Dr. David R. Gandara walks us through some of the most recent clinical trial data on non-small cell lung cancer from the 2021 American Society of Clinical Oncology Annual Meeting.

Dr. Rami Manochakian, a thoracic medical oncologist at the Mayo Clinic, dives into three clinical trials on developments in lung cancer treatment that were presented at the 2021 American Society of Clinical Oncology Annual Meeting.

ReachMD host Dr. Jacob Sands joins us to share key updates that were presented on lung cancer at the American Society of Clinical
Oncology Annual Meeting.

Dr. Fred R. Hirsch, Executive Director at the Center for Thoracic Oncology in the Tisch Cancer Institute at Mount Sinai and Associate Director of Biomarker Discovery for TCI discusses key studies presented at the 2021 American Society of Clinical Oncology meeting surrounding updates in lung cancer research.

In the field of breast cancer, how far have targeted therapies come? Dr. Maryam Lustberg, Assistant Professor of Internal Medicine in the Division of Medical Oncology at Ohio State University, shares some insight into the latest developments in the treatment of early-stage HER2-positive breast cancer.

How do surgical delays play a role in breast cancer outcomes? Dr. Samilia Obeng-Gyasi, an Assistant Professor of Surgery at Ohio State University, shares insight from her presentation at the 2021 American Society of Clinical Oncology Annual Meeting.